Remedisvir not looking good21 Aug 2020 22:53
A new study is raising fresh questions about the efficacy of Gilead Sciences Inc's anti-viral medication remdesivir in COVID-19 patients. A randomized, controlled trial of remdesivir in 584 moderately ill COVID-19 patients hospitalized with pneumonia yielded disappointing results in research published on Friday in JAMA.